Abstract:Background Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. Methods The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Results Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). Conclusions High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy has not been evaluated well in acute myeloid leukemia (AML), and basic information on immune checkpoint (IC) expression levels for comprehensively evaluating the prognosis of patients with AML is lacking. The prognostic value of ICs in AML patients was explored by using RNA-seq and mutant data of 176 AML patients from the Cancer Genome Atlas (TCGA) database and further validated the finding using bone marrow (BM) samples from 62 patients with de novo AML from our department by quantitative real-time PCR. Both TCGA data and validation results indicated that high expression of PD-1, PD-L1, and PD-L2 was associated with poor overall survival (OS) in AML patients. In addition, increased co-expression of PD-1 and CTLA-4 (3-year OS: 30% vs 0% (TGCA data), 57% vs 31% (validation group), respectively) or PD-L2 and CTLA-4 (3-year OS: 20% vs 0% (TGCA data), 57% vs 33% (validation group), respectively) correlated with poor AML OS (P < 0.05). Moreover, co-expression of PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 correlated with poor OS in AML patients with FLT3mut, RUNX1mut, and TET2mut, respectively (P < 0.05). High expression of ICs in the BM leukemia cells of AML patients correlated with poor OS. Co-expressions of PD-1/CTLA-4, PD-L2/CTLA-4, PD-1/PD-L1, PD-1/PD-L1/PD-L2, and PD-1/LAG-3 might be used as novel immune predictors for patient OS in AML, and might guide the best choice for precision immune checkpoint blockade in the future.

Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Higher Tim-3 expression concurrent with PD-1 in exhausted CD4+ and CD8+T cells in patients with acute myeloid leukemia

Increased PD-1+Tim-3+ Exhausted T Cells in Bone Marrow May Influence the Clinical Outcome of Patients with AML.

Characteristics of PD-1, TIM-3 Expression and Exhausted Phenotype in T Cells from Peripheral Blood and Bone Marrow in Patients with AML

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia

3103 – OPTIMAL COMBINATION OF IMMUNE CHECKPOINTS PREDICTS ADVERSE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Vδ2 T Cell Subsets, Defined by PD-1 and TIM-3 Expression, Present Varied Cytokine Responses in Acute Myeloid Leukemia Patients.

A Skewed Distribution and Increased PD-1+Vβ+CD4+/CD8+ T Cells in Patients with Acute Myeloid Leukemia

Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.

Increased TOX Expression Concurrent with PD-1, Tim-3, and CD244 Expression in T Cells from Patients with Acute Myeloid Leukemia.

Blockade of PD-1 and TIM-3 Ameliorates CD8+ T Cell Exhaustion in a Mouse Model of Chronic Myeloid Leukemia

Increased PD-1(+)Foxp3(+) gamma delta T cells associate with poor overall survival for patients with acute myeloid leukemia

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity.

Increasing Frequency of T Cell Immunosuppressive Receptor Expression in Cd4+And Cd8+T Cells May Related to T Cell Exhaustion and Immunosuppression in Patients with Aml

PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia